Pfizer PFE Biopharma — Acquired in-process research and development expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pfizer in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff.
The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pfizer's biopharma — acquired in-process research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pfizer's biopharma — acquired in-process research and development expenses?
- Pfizer (PFE) reported biopharma — acquired in-process research and development expenses of $137M in Q1 2026.
- How has Pfizer's biopharma — acquired in-process research and development expenses changed year-over-year?
- Pfizer's biopharma — acquired in-process research and development expenses increased by 1422.2% year-over-year, from $9M to $137M.
- What is the long-term trend for Pfizer's biopharma — acquired in-process research and development expenses?
- Over 3 years (2022 to 2025), Pfizer's biopharma — acquired in-process research and development expenses has grown at a -14.5% compound annual growth rate (CAGR), from $181M to $113M.
- What does biopharma — acquired in-process research and development expenses mean?
- Costs associated with the acquisition of early-stage research projects or pipeline assets from third parties. These expenses reflect the company's strategy to supplement internal R&D with external innovation.